These studies focus on the acute/hospital phase; they do not report post-COVID follistatin trajectories or evaluate sarcopenia outcomes, so within these data, a direct correlation between post-COVID follistatin levels and sarcopenia cannot be established [107,108,109]. Here, FST is linked to sarcopenia.